StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) stock

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.46−0.09 (-15.97%)

Close on Nov 17, 2026Market cap $830.71KP/E –Yield –

Aptevo Therapeutics cash

Cash and short-term investments held at the end of each period.

Aptevo Therapeutics's cash was $9.80M at Jun 30, 2026. For fiscal 2025 it was $21.62M, up 148.1% from the year before. Over ten years it grew 16.6% a year on average. The highest annual figure on record is $80.78M in fiscal 2017.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$21.62M+148.1%
FY2024Dec 31, 2024$8.71M-48.5%
FY2023Dec 31, 2023$16.90M-25.3%
FY2022Dec 31, 2022$22.64M-49.7%
FY2021Dec 31, 2021$45.04M+12.7%
FY2020Dec 31, 2020$39.98M+221.2%
FY2019Dec 31, 2019$12.45M-59.4%
FY2018Dec 31, 2018$30.64M-62.1%
FY2017Dec 31, 2017$80.78M+47.1%
FY2016Dec 31, 2016$54.93M+1084.5%
FY2015Dec 31, 2015$4.64M+29.1%
FY2014Dec 31, 2014$3.59M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.80M+4.1%
Q1 FY2026Mar 31, 2026$14.53M+579.1%
Q4 FY2025Dec 31, 2025$21.62M+148.1%
Q3 FY2025Sep 30, 2025$21.06M+171.6%
Q2 FY2025Jun 30, 2025$9.41M+16.7%
Q1 FY2025Mar 31, 2025$2.14M-79.1%
Q4 FY2024Dec 31, 2024$8.71M-48.5%
Q3 FY2024Sep 30, 2024$7.75M-59.4%
Q2 FY2024Jun 30, 2024$8.07M-61.6%
Q1 FY2024Mar 31, 2024$10.25M-59.5%
Q4 FY2023Dec 31, 2023$16.90M-25.3%
Q3 FY2023Sep 30, 2023$19.11M-13.7%
Q2 FY2023Jun 30, 2023$21.01M-28.6%
Q1 FY2023Mar 31, 2023$25.33M-27.6%
Q4 FY2022Dec 31, 2022$22.64M-49.7%
Q3 FY2022Sep 30, 2022$22.15M-57.5%
Q2 FY2022Jun 30, 2022$29.43M-51.3%
Q1 FY2022Mar 31, 2022$34.99M-39.2%
Q4 FY2021Dec 31, 2021$45.04M+12.7%
Q3 FY2021Sep 30, 2021$52.12M+109.0%
Q2 FY2021Jun 30, 2021$60.39M+694.8%
Q1 FY2021Mar 31, 2021$57.52M+369.3%
Q4 FY2020Dec 31, 2020$39.98M+221.2%
Q3 FY2020Sep 30, 2020$24.94M+41.1%
Q2 FY2020Jun 30, 2020$7.60M-63.7%
Q1 FY2020Mar 31, 2020$12.26M-66.9%
Q4 FY2019Dec 31, 2019$12.45M-59.4%
Q3 FY2019Sep 30, 2019$17.68M-53.0%
Q2 FY2019Jun 30, 2019$20.96M-53.1%
Q1 FY2019Mar 31, 2019$37.01M-40.0%
Q4 FY2018Dec 31, 2018$30.64M-62.1%
Q3 FY2018Sep 30, 2018$37.64M-61.1%
Q2 FY2018Jun 30, 2018$44.73M-8.0%
Q1 FY2018Mar 31, 2018$61.65M+0.6%
Q4 FY2017Dec 31, 2017$80.78M+47.1%
Q3 FY2017Sep 30, 2017$96.78M+59.5%
Q2 FY2017Jun 30, 2017$48.63M–
Q1 FY2017Mar 31, 2017$61.29M–
Q4 FY2016Dec 31, 2016$54.93M–
Q3 FY2016Sep 30, 2016$60.68M–

More Aptevo Therapeutics figures

See a number that looks wrong?